A Comparison of Certoparin and Unfractionated Heparin in the Prevention of Thromboembolic Events in Acutely Ill Medical Patients

PHASE3CompletedINTERVENTIONAL

Enrollment

3,254

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions

Thromboembolism

Interventions

DRUG

Certoparin

3000 U anti XA of certoparin in 0.3 ml solution, once daily

DRUG

Unfractionated Heparin

solution, 5000 IU of unfractionated heparin in 0.3 ml, 3 times daily

Trial Locations (1)

Novartis investigative sites, Nuremberg